Xilio Therapeutics Inc (XLO)
NASDAQ:XLO
Total Valuation
Xilio Therapeutics has a market cap or net worth of $49.21M. The enterprise value is -$81.37M.
Market Cap$49.21M
Enterprise Value-$81.37M
Share Statistics
Xilio Therapeutics has 5,782,511 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding5,782,511
Owned by Insiders13.02%
Owned by Institutions42.72%
Financial Efficiency
Xilio Therapeutics’s return on equity (ROE) is -0.99 and return on invested capital (ROIC) is -42.09%.
Return on Equity (ROE)-0.99
Return on Assets (ROA)-0.23
Return on Invested Capital (ROIC)-42.09%
Return on Capital Employed (ROCE)-0.43
Revenue Per Employee683.84K
Profits Per Employee-547.44K
Employee Count64
Asset Turnover0.28
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Xilio Therapeutics is ―. Xilio Therapeutics’s PEG ratio is 0.29.
PE Ratio―
PS Ratio17.11
PB Ratio21.23
Price to Fair Value21.23
Price to FCF-135.93
Price to Operating Cash Flow-142.50
PEG Ratio0.29
Income Statement
In the last 12 months, Xilio Therapeutics had revenue of 43.77M and earned -35.04M in profits. Earnings per share was -4.19.
Revenue43.77M
Gross Profit42.23M
Operating Income-41.98M
Pretax Income-35.04M
Net Income-35.04M
EBITDA-40.44M
Earnings Per Share (EPS)-4.19
Cash Flow
In the last 12 months, operating cash flow was -4.99M and capital expenditures -518.00K, giving a free cash flow of -5.51M billion.
Operating Cash Flow-4.99M
Free Cash Flow-5.51M
Free Cash Flow per Share-0.95
Dividends & Yields
Xilio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.21
52-Week Price Change-9.66%
50-Day Moving Average7.92
200-Day Moving Average9.57
Relative Strength Index (RSI)59.14
Average Volume (3m)43.00K
Important Dates
Xilio Therapeutics upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateMar 23, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Xilio Therapeutics as a current ratio of 2.58, with Debt / Equity ratio of 19.71%
Current Ratio2.58
Quick Ratio2.58
Debt to Market Cap<0.01
Net Debt to EBITDA3.23
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Xilio Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Xilio Therapeutics EV to EBITDA ratio is -15.29, with an EV/FCF ratio of -112.23.
EV to Sales14.13
EV to EBITDA-15.29
EV to Free Cash Flow-112.23
EV to Operating Cash Flow-123.88
Balance Sheet
Xilio Therapeutics has $137.53M in cash and marketable securities with $6.95M in debt, giving a net cash position of $130.58M billion.
Cash & Marketable Securities$137.53M
Total Debt$6.95M
Net Cash$130.58M
Net Cash Per Share$22.58
Tangible Book Value Per Share$0.42
Margins
Gross margin is 96.48%, with operating margin of -95.92%, and net profit margin of -80.05%.
Gross Margin96.48%
Operating Margin-95.92%
Pretax Margin-80.05%
Net Profit Margin-80.05%
EBITDA Margin-92.40%
EBIT Margin-95.92%
Analyst Forecast
The average price target for Xilio Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast588.40%
EPS Growth Forecast61.76%